S-(2-羟乙基)2,2-二甲基丙硫酸盐 | 153121-88-1

• 物质功能分类: 有机原料 - 有机硫化合物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 硫代羧酸及其衍生物
• 中文名称: S-(2-羟乙基)2,2-二甲基丙硫酸盐
• 英文名称: S-(2-hydroxyethyl) 2,2-dimethylpropanethioate
• 英文别名: S-pivaloyl-2-thioethanol；S-pivaloyl-2-mercaptoethanol；S-(2-hydroxyethyl) thiopivalate；2-pivaloylthioethanol
• CAS: 153121-88-1
• 化学式: C₇H₁₄O₂S
• 分子量: 162.253
• InChiKey: LIFQCFNVZCHRCI-UHFFFAOYSA-N

物化性质

• 沸点：
  232.4±23.0 °C(Predicted)
• 密度：
  1.062±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  62.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P264,P280,P302+P352,P305+P351+P338,P332+P313,P337+P313,P362
• 危险性描述：
  H315,H319
• 储存条件：
  存储条件：密封、干燥并置于惰性气体中，温度保持在2-8°C。

反应信息

• 作为反应物：
  描述：

  S-(2-羟乙基)2,2-二甲基丙硫酸盐 在 二异丙基铵盐四氮唑 、 三乙胺 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 反应 3.0h， 生成 5'-O-(4,4'-dimethoxytrityl)-2-N-(2,2'-bis(2-nitrophenyl)ethyloxycarbonyl)-2'-deoxyguanosine 3'-O-(S-pivaloyl-2-thioethyl) N,N-diisopropylphosphoramidite
  参考文献：
  名称：

  Photocleavable Protecting Groups as Nucleobase Protections Allowed the Solid-Phase Synthesis of Base-Sensitive SATE-Prooligonucleotides

  摘要：

  The first synthesis of oligodeoxynucleotide heteropolymers carrying base-sensitive S-pivaloylthioethyl (t-Bu-SATE) phosphotriester linkages has been performed. It is based on the use of 6-nitroveratryloxycarbonyl (NVOC) and 2,2'-bis(2-nitrophenyl)ethoxycarbonyl (diNPEOC) groups as nucleobase protections in combination with photolysis deprotection. The synthesis was realized using the phosphoramidite approach on solid support bearing a 1-(o-nitrophenyl)-1,3-propanediol linker. The removal of the protecting groups and the cleavage of the oligonucleotides from the solid support were accomplished in a single photolysis procedure upon UV irradiation at wavelengths >300 nn. Faster deprotection rates were observed for diNPEOC-protected nucleosides and oligomers than with NVOC-protected ones. The synthesis of pentanucleoside t-Bu-SATE-phosphotriesters d((5')TpCpCpCpTp(3')), d((5')TpApApApAp(3')), and d((5')TpGpGpGpTp(3')) and of dodecanucleoside t-Bu-SATE-phosphotriesters and -phosphorothioate d((5')ApCpApCpCpCpApApTpTpCpTp(3')) and d((5')ApGpApApTpTpGpGpGpTpGpTp(3')) demonstrated the efficiency of the method.

  DOI：

  10.1021/jo990479h
• 作为产物：
  描述：

  三甲基乙酰氯 在 sodium hydride 作用下， 以 四氢呋喃 、 mineral oil 为溶剂， 反应 5.0h， 生成 S-(2-羟乙基)2,2-二甲基丙硫酸盐
  参考文献：
  名称：

  Nucleotide mimics and their prodrugs

  摘要：

  本发明涉及核苷二磷酸模拟物和核苷三磷酸模拟物，其中包含二磷酸或三磷酸基团模拟物，以及可选的糖修饰和/或碱基修饰。本发明的核苷酸模拟物，以药学上可接受的盐、药学上可接受的前药或药物配方的形式，可用作抗病毒、抗微生物和抗癌剂。本发明提供了一种治疗病毒感染、微生物感染和增生性疾病的方法。本发明还涉及包含本发明化合物的药物组合物，可选地与其他药理活性剂结合。

  公开号：

  US20040059104A1

文献信息

• CYCLOPENTENYL PURINE DERIVATIVE OR SALT THEREOF
  申请人：Fujifilm Corporation

  公开号：US20210155644A1

  公开（公告）日：2021-05-27

  An object of the present invention is to provide a compound exhibiting an excellent drug efficacy as an anti-adenoviral agent, and an anti-adenoviral agent. The present invention provides an anti-adenoviral agent including a compound represented by General Formula [1] (in the formula, R 1 represents a hydrogen atom, a halogen atom, an amino group which may be substituted, a monocyclic nitrogen-containing heterocyclic ring group which may be substituted (provided that a nitrogen atom forming the ring is bonded to a carbon atom to which R 1 is bonded), a monocyclic nitrogen- and oxygen-containing heterocyclic ring group which may be substituted (provided that a nitrogen atom forming the ring is bonded to a carbon atom to which R 1 is bonded), a C 1-6 alkoxy group which may be substituted, a hydroxyl group which may be protected, or the like; R 2 represents a hydrogen atom or an amino protecting group; R 3 represents a C 1-20 alkoxy group which may be substituted, an aryloxy group which may be substituted, an amino group which may be substituted, or the like; R 4 represents a C 1-20 alkoxy group which may be substituted, an aryloxy group which may be substituted, an amino group which may be substituted, or the like; and X represents an oxygen atom or a sulfur atom) or a salt thereof.

  本发明的一个目的是提供一种作为抗腺病毒药剂具有优异药效的化合物，以及一种抗腺病毒药剂。本发明提供了一种包括由通式[1]表示的化合物的抗腺病毒药剂 （在公式中，R 1 表示氢原子、卤素原子、可能被取代的氨基、可能被取代的单环氮含杂环基团（前提是形成环的氮原子与R 1 结合的碳原子相结合）、可能被取代的单环氮和氧含杂环基团（前提是形成环的氮原子与R 1 结合的碳原子相结合）、可能被取代的C 1-6 烷氧基、可能被保护的羟基等；R 2 表示氢原子或氨基保护基团；R 3 表示可能被取代的C 1-20 烷氧基、可能被取代的芳氧基、可能被取代的氨基等；R 4 表示可能被取代的C 1-20 烷氧基、可能被取代的芳氧基、可能被取代的氨基等；X表示氧原子或硫原子）或其盐。
• 喹啉类化合物、其制备方法、药物组合物和用途
  申请人：瀚海新拓（杭州）生物医药有限公司

  公开号：CN111777638A

  公开（公告）日：2020-10-16

  一种如通式I所示的化合物、其药学上可接受的盐、或其代谢产物，以及其制备方法、药物组合物和用途。所示通式I所示的化合物、其药学上可接受的盐、或其代谢产物对病毒感染具有良好的治疗作用，毒副作用较小，可用于预防或治疗病毒感染。
• [EN] CYCLIC PHOSPHATES AND CYCLIC PHOSPHORAMIDATES FOR THE TREATMENT OF NEUROLOGIC DISORDERS<br/>[FR] PHOSPHATES CYCLIQUES ET PHOSPHORAMIDATES CYCLIQUES POUR LE TRAITEMENT DE TROUBLES NEUROLOGIQUES
  申请人：RETROPHIN INC

  公开号：WO2017099822A1

  公开（公告）日：2017-06-15

  Compounds having the following formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, D, E and R1 are as defined herein, are provided. Methods comprising the use of such compounds for the treatment of neurological disorders, such as pantothenate kinase-associated neurodegeneration, and pharmaceutical compositions containing such compounds, and their use in the treatment of neurological disorders, also are provided.

  提供具有以下化学式（I）的化合物及其药用可接受的盐，其中A、B、D、E和R1的定义如本文所述。提供了使用这些化合物治疗神经系统疾病（如泛酸激酶相关性神经退行性疾病）的方法，以及含有这些化合物的药物组合物，以及它们在治疗神经系统疾病中的用途。
• CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF
  申请人：FUJIFILM Corporation

  公开号：US20210147456A1

  公开（公告）日：2021-05-20

  An object of the present invention is to provide a compound exhibiting an excellent drug efficacy as an anti-adenoviral agent, and an anti-adenoviral agent. The present invention provides a compound represented by General Formula [1] (in the formula, R 1 represents a halogen atom, an amino group which may be substituted, a C 1-6 alkoxy group which may be substituted, a hydroxyl group which may be protected, or the like; R 2 represents a hydrogen atom or an amino protecting group; R 3 represents a C 1-20 alkoxy group which may be substituted, an aryloxy group which may be substituted, an amino group which may be substituted, or the like; R 4 represents a C 1-20 alkoxy group which may be substituted, an aryloxy group which may be substituted, an amino group which may be substituted, or the like); or a salt thereof.

  本发明的一个目的是提供一种作为抗腺病毒药剂的化合物，以及一种抗腺病毒药剂。本发明提供一种由通式[1]表示的化合物 （在该式中，R 1 代表卤原子，可能被取代的氨基，可能被取代的C 1-6 烷氧基，可能被保护的羟基等；R 2 代表氢原子或氨基保护基；R 3 代表可能被取代的C 1-20 烷氧基，可能被取代的芳氧基，可能被取代的氨基等；R 4 代表可能被取代的C 1-20 烷氧基，可能被取代的芳氧基，可能被取代的氨基等）；或其盐。
• Synthesis of SATE Prodrug of 6'-Fluoro-6'-methyl-5'-noradenosine Nucleoside Phosphonic Acid as a New Class of Anti-HIV Agent
  作者：Hua Li、Jin-Cheol Yoo、Young-Chan Baik、Won-Jae Lee、Joon-Hee Hong

  DOI：10.5012/bkcs.2010.31.9.2514

  日期：2010.9.20

  and synthetic nucleosides in which the furanose oxygen has been replaced by a methylene group. This replacement changes the furanose ring into a cyclopentane. The expected similarity in bond lengths and bond angles of the tetrahydrofuran and cyclopentane rings allows these analogues to behave as substrates or inhibitors of the enzymes in living cells. Therefore, the carbocyclic nucleosides possess a wide

  是一组结构上类似于天然和合成核苷的化合物，其中呋喃糖氧已被亚甲基取代。这种替换将呋喃糖环变成了环戊烷。四氢呋喃和环戊烷环的键长和键角的预期相似性允许这些类似物充当活细胞中酶的底物或抑制剂。因此，碳环核苷具有广泛的生物活性，如抗病毒和抗肿瘤作用。尽管核苷抗病毒活性的药效团尚未完全确定，但结构修饰的5'-去甲核苷膦酸如d4AP（